Department of Infectious Diseases, University Hospital, Goethe University Frankfurt am Main, Frankfurt, Germany.
Praxiszentrum Alte Mälzerei, Regensburg, Germany.
AIDS Patient Care STDS. 2021 Feb;35(2):33-38. doi: 10.1089/apc.2020.0223.
Breastfeeding (BF) in mothers living with HIV (MLWH) is still discussed controversially in resource-rich settings. In Germany, where formula feeding is recommended for MLWH single BF cases have been reported, but no systematic data collection and analysis are available so far. This study, titled HELENE, aims to fill this data gap. A questionnaire covering the course of BF was distributed by a graduate student visiting each study site. Information was collected from patient files and by personal communication with the health care provider. Primary study objectives were the duration of BF and the maternal antiretroviral treatment (ART). Fifteen treatment centers across Germany contributed a total of 42 BF cases, observed from May 2009 to July 2020. There was an increasing number of BF cases over time. The median duration of BF was 20 weeks varying from single BF of colostrum to 104 weeks. All BF women except one elite controller received ART: 39% non-nucleoside reverse transcriptase inhibitor-, 37% INSTI-, 29% protease inhibitor-based regimens; one woman was on maraviroc. Thirty-nine percent of the ART regimens included drugs that were not recommended by the German-Austrian pregnancy guidelines. Our findings highlight the diversity of BF cases in Germany in terms of duration, maternal ART, and monitoring. Since the number of BF cases is increasing, guidelines are obliged to implement more detailed recommendations on BF, the monitoring of BF mothers, and the follow-up of the infants. There is an urgent need for prospective national and European data collections to further improve HIV prevention of mother-to-child transmission (PMTCT) in the setting of BF.
在资源丰富的环境中,HIV 阳性母亲(MLWH)进行母乳喂养(BF)仍然存在争议。在德国,推荐 MLWH 使用配方奶喂养,但目前尚无系统的数据收集和分析。本研究题为 HELENE,旨在填补这一数据空白。一名研究生在访问每个研究地点时分发了一份涵盖 BF 过程的问卷。信息是从患者档案中收集的,并通过与医疗保健提供者的个人交流获得。主要研究目标是 BF 的持续时间和母亲的抗逆转录病毒治疗(ART)。德国的 15 个治疗中心共观察了 42 例 BF 病例,从 2009 年 5 月至 2020 年 7 月。随着时间的推移,BF 病例的数量逐渐增加。BF 的中位持续时间为 20 周,从单次 BF 初乳到 104 周不等。除了一名精英控制器外,所有接受 BF 的女性都接受了 ART:39%的女性接受非核苷类逆转录酶抑制剂、37%的 INSTI、29%的蛋白酶抑制剂为基础的方案;一名女性接受了 maraviroc。39%的 ART 方案包含了不符合德国-奥地利妊娠指南推荐的药物。我们的发现强调了德国 BF 案例在持续时间、母亲 ART 和监测方面的多样性。由于 BF 病例的数量在增加,指南有义务对 BF、BF 母亲的监测以及婴儿的随访提出更详细的建议。迫切需要进行全国性和欧洲前瞻性数据收集,以进一步改善 BF 环境下的母婴 HIV 预防(PMTCT)。